The pharmaceutical industry scored a big win on June 7 in the Texas Supreme Court. Not only did the court knock out a $3.6 million verdict against a Johnson & Johnson subsidiary that makes the drug Remicade, but it set a new, tougher standard in the state for bringing cases alleging failure-to-warn and fraud.
In the 55-page opinion, the court adopted the “learned intermediary” rule, holding that a prescription drug maker fulfills its duty to warn a patient of its product’s risks if it gives adequate warnings to the prescribing doctor. The decision brings Texas into line with at least 35 states whose highest courts also have endorsed this approach. The case was closely watched in the pharma community and beyond, attracting six amicus briefs, including filings from the Washington Legal Foundation, the Pacific Legal Foundation and the Product Liability Advisory Council.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
